Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 0.63 |
| ▸ | F10 | P00742 | 4/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6308115 | 0.90 | MAPT (0.59) | CCR2F10KMT2AMAPT | |
| SCHEMBL6303111 | 0.87 | MAPT (0.63) | CCR2F10MAPT | |
| SCHEMBL6596946 | 0.87 | MAPT (0.59) | F10KMT2AMAPT | |
| SCHEMBL6308083 | 0.86 | CCR2 (0.81) | CCR2F10ABCB11 | |
| SCHEMBL6300567 | 0.85 | CCR2 (0.67) | CCR2ABCB11KMT2AMAPT | |
| SCHEMBL6785298 | 0.84 | ABCB11 (0.76) | CCR2ABCB11MAPT | |
| SCHEMBL6598529 | 0.84 | F10 (0.52) | CCR2F10MAPT | |
| SCHEMBL6599157 | 0.84 | CCR2 (0.66) | CCR2ABCB11KMT2AMAPT | |
| SCHEMBL6596843 | 0.83 | CCR2 (0.65) | CCR2F10ABCB11KMT2AMAPT | |
| SCHEMBL6357264 | 0.83 | CCR2 (0.65) | CCR2ABCB11KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953809-B2 | Monocyte chemoattractant protein-1 inhibitor compounds | ZENECA LIMITED (GB) | 2005-10-11 | — | — | US | disclosed |
| US-6911465-B1 | Anti-inflammatory indole derivatives | ASTRAZENECA AB (SE) | 2005-06-28 | — | — | US | disclosed |
| US-20050026975-A1 | Anti-inflammatory indole derivatives | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | US | disclosed |
| EP-1150954-B1 | ANTI-IMFLAMMATORY INDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-10-13 | — | — | EP | disclosed |
| EP-1003504-B1 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-07-02 | — | — | EP | disclosed |
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | ZENECA LIMITED | 2003-06-26 | — | — | US | disclosed |
| US-6569888-B1 | Such as ethyl-N-(dichlorobenzyl)-4-(3-hydroxypropylthio) indole-2-carboxylate; for treatment of arthritis | ASTRAZENECA AB (SE) | 2003-05-27 | — | — | US | disclosed |
| EP-1159269-B1 | ANTI-IMFLAMMATORY INDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-03-26 | — | — | EP | disclosed |
| US-6441004-B1 | INDOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | ZENECA LIMITED (GB) | 2002-08-27 | — | — | US | disclosed |
| EP-1159269-A1 | ANTI-IMFLAMMATORY INDOLE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-05 | — | — | EP | disclosed |
| EP-1150954-A1 | ANTI-IMFLAMMATORY INDOLE DERIVATIVES | AstraZeneca AB (SE) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000046195-A1 | ANTI-INFLAMMATORY INDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | disclosed |
| WO-2000046198-A1 | ANTI-INFLAMMATORY INDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | disclosed |
| EP-1003504-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | AstraZeneca UK Limited (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999007351-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ZENECA LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | CCL2, CCL11, CCR1 | CCR2 4/4885F10 485/4885ABCB11 506/4885 |
| US-20050026975-A1 | Anti-inflammatory indole derivatives | CCR5, CCR2, CCL5 | CCR2 2/4885F10 4214/4885ABCB11 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.